Benjamin Click
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 42 | 2025 | 254 | 14.200 |
Why?
| | Inflammatory Bowel Diseases | 33 | 2026 | 358 | 8.670 |
Why?
| | Colitis, Ulcerative | 14 | 2025 | 143 | 3.480 |
Why?
| | Ileum | 13 | 2025 | 112 | 3.080 |
Why?
| | Recurrence | 17 | 2025 | 1110 | 2.990 |
Why?
| | Colonoscopy | 10 | 2025 | 250 | 2.810 |
Why?
| | Biological Products | 10 | 2026 | 237 | 2.440 |
Why?
| | Gastrointestinal Agents | 8 | 2025 | 67 | 2.180 |
Why?
| | Ustekinumab | 9 | 2025 | 17 | 1.980 |
Why?
| | Colon | 9 | 2025 | 300 | 1.500 |
Why?
| | Ileostomy | 4 | 2025 | 25 | 1.340 |
Why?
| | Patient-Centered Care | 4 | 2024 | 550 | 1.210 |
Why?
| | Postoperative Complications | 9 | 2025 | 2797 | 1.050 |
Why?
| | Mesentery | 2 | 2024 | 45 | 1.040 |
Why?
| | Secondary Prevention | 2 | 2025 | 241 | 1.030 |
Why?
| | Remission Induction | 8 | 2025 | 309 | 0.950 |
Why?
| | Holistic Health | 1 | 2024 | 15 | 0.870 |
Why?
| | Anastomosis, Surgical | 6 | 2025 | 159 | 0.830 |
Why?
| | Adult | 43 | 2026 | 39177 | 0.830 |
Why?
| | Health Expenditures | 3 | 2020 | 193 | 0.820 |
Why?
| | Retrospective Studies | 25 | 2026 | 16273 | 0.800 |
Why?
| | Humans | 73 | 2026 | 141187 | 0.770 |
Why?
| | Delivery of Health Care | 2 | 2020 | 961 | 0.750 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2021 | 1250 | 0.750 |
Why?
| | Diverticulitis | 1 | 2022 | 8 | 0.740 |
Why?
| | Patient Acceptance of Health Care | 5 | 2026 | 878 | 0.740 |
Why?
| | Health Care Costs | 3 | 2020 | 424 | 0.730 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 31 | 0.710 |
Why?
| | C-Reactive Protein | 5 | 2026 | 418 | 0.680 |
Why?
| | Dermatologic Agents | 1 | 2021 | 69 | 0.670 |
Why?
| | Cost of Illness | 2 | 2020 | 312 | 0.640 |
Why?
| | Risk Factors | 14 | 2025 | 10438 | 0.640 |
Why?
| | Proctocolectomy, Restorative | 4 | 2024 | 23 | 0.620 |
Why?
| | Gastric Bypass | 1 | 2020 | 119 | 0.580 |
Why?
| | Health Resources | 2 | 2018 | 129 | 0.580 |
Why?
| | Colonic Pouches | 3 | 2024 | 15 | 0.570 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 85 | 0.570 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 98 | 0.570 |
Why?
| | Middle Aged | 30 | 2026 | 34434 | 0.550 |
Why?
| | Colitis | 1 | 2020 | 266 | 0.530 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 852 | 0.530 |
Why?
| | Drug Monitoring | 3 | 2026 | 217 | 0.520 |
Why?
| | Bariatric Surgery | 1 | 2020 | 218 | 0.510 |
Why?
| | Obesity, Morbid | 1 | 2020 | 273 | 0.490 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 222 | 0.480 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 246 | 0.480 |
Why?
| | Adenoma | 1 | 2018 | 220 | 0.480 |
Why?
| | Severity of Illness Index | 9 | 2025 | 2892 | 0.470 |
Why?
| | Eosinophilia | 1 | 2017 | 218 | 0.460 |
Why?
| | Male | 39 | 2026 | 69783 | 0.460 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 92 | 0.450 |
Why?
| | Blood Component Removal | 1 | 2015 | 27 | 0.450 |
Why?
| | Hypertriglyceridemia | 1 | 2015 | 39 | 0.450 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 204 | 0.440 |
Why?
| | Constriction, Pathologic | 4 | 2023 | 238 | 0.430 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 482 | 0.430 |
Why?
| | Spondylarthritis | 2 | 2025 | 50 | 0.420 |
Why?
| | Quality Improvement | 2 | 2020 | 1244 | 0.420 |
Why?
| | Prospective Studies | 14 | 2022 | 7739 | 0.420 |
Why?
| | Pancreatitis | 1 | 2015 | 136 | 0.420 |
Why?
| | Female | 38 | 2026 | 75515 | 0.420 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 289 | 0.420 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1448 | 0.400 |
Why?
| | Treatment Outcome | 11 | 2025 | 11120 | 0.390 |
Why?
| | Quality of Life | 10 | 2022 | 2999 | 0.390 |
Why?
| | Sweet Syndrome | 2 | 2023 | 9 | 0.390 |
Why?
| | Hospitalization | 4 | 2026 | 2255 | 0.360 |
Why?
| | Mental Disorders | 2 | 2017 | 1120 | 0.350 |
Why?
| | Cecum | 2 | 2023 | 32 | 0.340 |
Why?
| | Leukocyte L1 Antigen Complex | 3 | 2026 | 38 | 0.340 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 802 | 0.320 |
Why?
| | Disease Progression | 6 | 2022 | 2793 | 0.320 |
Why?
| | Dilatation | 2 | 2020 | 69 | 0.320 |
Why?
| | Anemia | 3 | 2016 | 177 | 0.320 |
Why?
| | Registries | 8 | 2022 | 2135 | 0.310 |
Why?
| | Endoscopy | 2 | 2023 | 322 | 0.310 |
Why?
| | Pennsylvania | 6 | 2018 | 133 | 0.300 |
Why?
| | Anus Diseases | 2 | 2020 | 9 | 0.300 |
Why?
| | Telemedicine | 1 | 2018 | 891 | 0.290 |
Why?
| | Aged | 12 | 2023 | 24574 | 0.280 |
Why?
| | Biological Therapy | 3 | 2022 | 27 | 0.270 |
Why?
| | Young Adult | 10 | 2025 | 13673 | 0.260 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 618 | 0.260 |
Why?
| | Pouchitis | 2 | 2024 | 8 | 0.260 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 2070 | 0.250 |
Why?
| | Colectomy | 2 | 2024 | 107 | 0.240 |
Why?
| | Risk | 2 | 2019 | 904 | 0.240 |
Why?
| | Risk Assessment | 4 | 2025 | 3490 | 0.240 |
Why?
| | Biopsy | 3 | 2024 | 1081 | 0.240 |
Why?
| | Necrosis | 2 | 2023 | 249 | 0.230 |
Why?
| | Brain | 1 | 2017 | 2858 | 0.220 |
Why?
| | Biomarkers | 4 | 2025 | 4174 | 0.210 |
Why?
| | Neoplasms | 1 | 2019 | 2741 | 0.200 |
Why?
| | Gastroenterology | 1 | 2025 | 182 | 0.200 |
Why?
| | Social Isolation | 1 | 2023 | 66 | 0.200 |
Why?
| | Comparative Effectiveness Research | 2 | 2021 | 164 | 0.190 |
Why?
| | Reoperation | 2 | 2022 | 588 | 0.190 |
Why?
| | Anus Neoplasms | 1 | 2021 | 35 | 0.170 |
Why?
| | Intestinal Mucosa | 2 | 2024 | 631 | 0.170 |
Why?
| | Time Factors | 6 | 2025 | 6956 | 0.170 |
Why?
| | Propensity Score | 2 | 2020 | 328 | 0.170 |
Why?
| | Skin Neoplasms | 2 | 2019 | 849 | 0.170 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2021 | 38 | 0.170 |
Why?
| | Economics, Medical | 1 | 2020 | 6 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.160 |
Why?
| | Rheumatic Diseases | 1 | 2021 | 92 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 232 | 0.160 |
Why?
| | Fibrosis | 2 | 2020 | 541 | 0.160 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 232 | 0.160 |
Why?
| | Infliximab | 1 | 2020 | 111 | 0.150 |
Why?
| | Intestinal Obstruction | 1 | 2020 | 52 | 0.150 |
Why?
| | Pulmonary Embolism | 1 | 2022 | 239 | 0.150 |
Why?
| | Electronic Health Records | 2 | 2018 | 1122 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 264 | 0.150 |
Why?
| | Gastrectomy | 1 | 2020 | 133 | 0.150 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1243 | 0.150 |
Why?
| | Adolescent | 6 | 2022 | 22007 | 0.150 |
Why?
| | Sigmoidoscopy | 1 | 2018 | 14 | 0.140 |
Why?
| | Drug Substitution | 1 | 2019 | 60 | 0.140 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 1116 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5636 | 0.140 |
Why?
| | Deprescriptions | 1 | 2019 | 37 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2018 | 1490 | 0.140 |
Why?
| | Health Services Misuse | 1 | 2018 | 35 | 0.140 |
Why?
| | Linear Models | 1 | 2020 | 857 | 0.140 |
Why?
| | Pyrroles | 1 | 2019 | 210 | 0.140 |
Why?
| | Surveys and Questionnaires | 6 | 2025 | 5929 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 337 | 0.130 |
Why?
| | Lymphoma | 1 | 2019 | 228 | 0.130 |
Why?
| | Piperidines | 1 | 2019 | 216 | 0.130 |
Why?
| | Thyroid Neoplasms | 1 | 2021 | 327 | 0.130 |
Why?
| | Disease Management | 2 | 2020 | 633 | 0.130 |
Why?
| | Cohort Studies | 4 | 2025 | 5799 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1073 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2017 | 74 | 0.130 |
Why?
| | Models, Organizational | 1 | 2017 | 147 | 0.120 |
Why?
| | Skin Diseases | 1 | 2018 | 147 | 0.120 |
Why?
| | Dermatology | 1 | 2018 | 122 | 0.120 |
Why?
| | Unemployment | 1 | 2016 | 43 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 642 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 262 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2018 | 5200 | 0.120 |
Why?
| | Intestines | 1 | 2019 | 357 | 0.120 |
Why?
| | United States | 6 | 2025 | 15220 | 0.120 |
Why?
| | Adalimumab | 1 | 2015 | 55 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 477 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2020 | 3588 | 0.110 |
Why?
| | Weight Loss | 1 | 2020 | 789 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2794 | 0.110 |
Why?
| | Inflammation | 2 | 2024 | 2890 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 908 | 0.100 |
Why?
| | Hemoglobins | 1 | 2015 | 361 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 914 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 772 | 0.090 |
Why?
| | Patient Care Team | 1 | 2017 | 664 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1176 | 0.090 |
Why?
| | Feces | 2 | 2026 | 504 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2902 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4073 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1662 | 0.090 |
Why?
| | Logistic Models | 3 | 2018 | 2086 | 0.070 |
Why?
| | Needs Assessment | 2 | 2022 | 382 | 0.070 |
Why?
| | Hypertension | 1 | 2016 | 1252 | 0.070 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1074 | 0.070 |
Why?
| | Immunologic Factors | 2 | 2021 | 248 | 0.060 |
Why?
| | Iron Compounds | 2 | 2016 | 7 | 0.060 |
Why?
| | Blood Sedimentation | 2 | 2016 | 40 | 0.060 |
Why?
| | Age Factors | 2 | 2025 | 3292 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 38 | 0.060 |
Why?
| | Janus Kinase Inhibitors | 1 | 2025 | 27 | 0.060 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 80 | 0.060 |
Why?
| | Prevalence | 2 | 2025 | 2772 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 212 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 704 | 0.050 |
Why?
| | Mitomycin | 1 | 2021 | 33 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2022 | 7856 | 0.040 |
Why?
| | Resilience, Psychological | 1 | 2023 | 129 | 0.040 |
Why?
| | Sutures | 1 | 2022 | 60 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1261 | 0.040 |
Why?
| | Fistula | 1 | 2022 | 47 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 750 | 0.040 |
Why?
| | Operative Time | 1 | 2022 | 154 | 0.040 |
Why?
| | Societies, Medical | 1 | 2025 | 855 | 0.040 |
Why?
| | Fluorouracil | 1 | 2021 | 206 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 218 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 282 | 0.040 |
Why?
| | Safety | 1 | 2022 | 356 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1556 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2023 | 565 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2058 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2746 | 0.040 |
Why?
| | Phenotype | 2 | 2017 | 3166 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1763 | 0.030 |
Why?
| | Patient Preference | 1 | 2020 | 205 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2022 | 1018 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1597 | 0.030 |
Why?
| | Laparoscopy | 1 | 2022 | 463 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1601 | 0.030 |
Why?
| | Anticoagulants | 1 | 2022 | 675 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 696 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1970 | 0.030 |
Why?
| | Animals | 1 | 2019 | 37657 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1082 | 0.030 |
Why?
| | Qualitative Research | 1 | 2023 | 1516 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 433 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 554 | 0.030 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 190 | 0.030 |
Why?
| | Bacillus subtilis | 2 | 1972 | 66 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1483 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1819 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 582 | 0.030 |
Why?
| | Bacteriophages | 2 | 1972 | 107 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 441 | 0.020 |
Why?
| | DNA, Viral | 2 | 1972 | 366 | 0.020 |
Why?
| | Lysogeny | 1 | 1971 | 5 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1787 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2015 | 528 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 703 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3709 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1865 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2172 | 0.020 |
Why?
| | Mutation | 2 | 1972 | 4013 | 0.010 |
Why?
| | DNA Replication | 2 | 1972 | 240 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 2 | 1972 | 40 | 0.010 |
Why?
| | Tritium | 2 | 1972 | 72 | 0.010 |
Why?
| | Uridine | 2 | 1972 | 30 | 0.010 |
Why?
| | Mitomycins | 1 | 1972 | 4 | 0.010 |
Why?
| | Nitrosoguanidines | 1 | 1971 | 1 | 0.010 |
Why?
| | Temperature | 2 | 1972 | 669 | 0.010 |
Why?
| | Cesium | 1 | 1971 | 20 | 0.010 |
Why?
| | Cell-Free System | 1 | 1971 | 55 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1971 | 60 | 0.010 |
Why?
| | Mutagens | 1 | 1971 | 24 | 0.010 |
Why?
| | Oxides | 1 | 1971 | 49 | 0.010 |
Why?
| | Muramidase | 1 | 1971 | 79 | 0.010 |
Why?
| | Culture Media | 1 | 1971 | 163 | 0.010 |
Why?
| | Deuterium | 1 | 1971 | 98 | 0.010 |
Why?
| | Chlorides | 1 | 1971 | 138 | 0.010 |
Why?
| | DNA, Bacterial | 1 | 1971 | 339 | 0.010 |
Why?
| | Viral Proteins | 1 | 1972 | 369 | 0.000 |
Why?
| | Bacteriolysis | 1 | 1972 | 9 | 0.000 |
Why?
| | Transferases | 1 | 1972 | 31 | 0.000 |
Why?
| | Adenine | 1 | 1972 | 301 | 0.000 |
Why?
| | Virus Replication | 1 | 1972 | 532 | 0.000 |
Why?
|
|
Click's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|